Navigation Links
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Date:4/15/2008

mized, controlled, open-label study is projected to enroll approximately 200 treatment-naive HIV-infected adult patients at more than 20 sites in North America, Central America, Europe and South Africa. Patients coinfected with hepatitis B or C may be included in the study.

The primary efficacy endpoint of the study is the mean change from baseline in viral load (log10 HIV RNA) at week 48 of treatment. A key secondary efficacy endpoint is the proportion of patients with plasma HIV RNA less than 50 copies/mL at week 48 of treatment.

The study will be conducted in two stages. In the first stage, 80 patients will be randomized (40 per treatment arm) into the study. When the 80 subjects from the first stage have completed 24 weeks of treatment, a formal interim analysis will be conducted and the results presented to an independent Data Safety Monitoring Board (DSMB) to assure the safety of the study participants. The study will be extended to stage 2 based on the results of the 24-week interim analysis; at which time an additional 120 patients (60 per treatment arm) will be enrolled. The final analysis will be conducted at week 48 of treatment for all patients.

Atazanavir boosted by ritonavir was selected for use in this study because it is recommended as an option for first-line therapy in both the International AIDS Society and Department of Health and Human Services guidelines for antiretroviral therapy. Additionally, it has been shown to have a more favorable lipid profile than other drugs in the PI class.

The study is being sponsored by Schering-Plough with support from Bristol-Myers Squibb.

About Vicriviroc Ongoing Phase III Studies in Treatment-Experienced Patients

Schering-Plough is currently enrolling patients in two large global Phase III clinical studies with vicriviroc in adult treatment-experienced HIV-infected patients with R5-type virus only.

The two studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Schering-Plough Reports Top-Line Results of the IDEAL Study
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... compares favorably with endoscopic resection for advanced disease, and ... SUNNYVALE, Calif., June 3 Results from ... Digestive Disease Week (DDW) in Chicago this week, revealing ... the HALO ablation system for eradicating a pre-cancerous esophageal ...
... And All Subsequent Study Visits - , , ... Ltd., (DSP) announced today that positive results from a phase ... with schizophrenia have been published in The Journal of ... involving 180 patients with acute schizophrenia, evaluated a single fixed ...
Cached Medicine Technology:Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons 2Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons 3Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons 4Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... In people with sex addiction, pornography affects the brain ... drug addicts as they consume drugs, a new study ... between patients who have compulsive sexual behavior and healthy ... author Dr. Valerie Voon, of the University of Cambridge ... Voon,s research involved 19 men with sex addiction and ...
(Date:7/11/2014)... 11, 2014 The report “Probiotics ... Nutrients, Animal Feed), Applications (Regular, Therapeutic, Preventive Health ... Trends & Forecasts to 2019 ” defines and ... and forecasting of the market value of probiotic ... driving and restraining factors for the global market ...
(Date:7/11/2014)... Biostimulants are widely applied in turf and ... These also help turf and ornamentals in absorption of ... ornamentals, and flowers appear healthy and strong as a ... from the last few years. The most dominating region ... with around 40% share in 2013, and is estimated ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... A problem in the lining of blood vessels may play ... a new study. The condition, called endothelial dysfunction, involves ... of cells that line blood vessels. Nitric oxide is crucial ... flow and the delivery of oxygen and nutrients to tissues. ...
... York, New YorkPremiums for employer-sponsored family health insurance increased ... to 2009, more than three times faster than median ... insurance is buying less. The report found that deductibles ... plus higher out-of-pocket costs are putting working families, budgets ...
... , WEDNESDAY, Dec. 1 (HealthDay News) -- Being exposed ... linked to dementia, a new study of agricultural workers suggests. ... who were in their 40s and 50s and had worked ... intellectual abilities were assessed twice, using nine tests designed to ...
... are nearly three times as likely as civilians to ... at Portland State University (PSU) and Oregon Health & ... Among Women With U.S. Military Service: A Hidden Epidemic?" ... Services , a journal published by the American Psychiatric ...
... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, ... proven superior to other regimens for breast cancer that ... better for some women whose cancers haven,t spread, a ... these "node-negative" cancers, the drug combination of docetaxel, doxorubicin ...
... variations in a gene as important contributors to neuroblastoma, ... study team, led by researchers at The Children,s Hospital ... gene increase the risk of developing an aggressive form ... to drive the cancer,s progression once it forms. ...
Cached Medicine News:Health News:New Piece of Alzheimer's Puzzle Identified 2Health News:New report: Employer health insurance premiums increased 41 percent from 2003 to 2009 2Health News:New report: Employer health insurance premiums increased 41 percent from 2003 to 2009 3Health News:New report: Employer health insurance premiums increased 41 percent from 2003 to 2009 4Health News:Working With Pesticides May Affect Memory and More 2Health News:Suicide rate among young women veterans more than twice that of civilians 2Health News:Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph 2Health News:Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph 3Health News:New gene for childhood cancer neuroblastoma is discovered 2Health News:New gene for childhood cancer neuroblastoma is discovered 3
Designated most popular model or size. 4 mm wide tip....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Medicine Products: